NCT03472326 - Study to Evaluate the Efficacy of GS-9131 Functional Monotherapy in Human Immunodeficiency Virus (HIV)-1-Infected Adults Failing a Nucleos(t)Ide Reverse Transcriptase Inhibitor-Containing Regimen With Nucleos(t)Ide Reverse Transcriptase Inhibitor Resistant Virus | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 3, 2018

Primary Completion Date

December 9, 2019

Study Completion Date

December 9, 2019

Conditions

HIV-1-infection

Interventions

DRUG

GS-9131

Tablet(s) administered orally once daily

DRUG

BIC

Tablet(s) administered orally once daily

DRUG

TAF

Tablet(s) administered orally once daily

DRUG

ARV regimen

ARV regimen may consist of the ARV agents containing nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitor (NNRTI)

DRUG

DRV

Tablet(s) administered orally once daily

DRUG

RTV

Tablet(s) administered orally once daily

Trial Locations (2)

10005

Joint Clinical Research Centre, Kampala

Unknown

Joint Research Ethics Committee for the University of Zimbabwe College of Health Sciences and Parirenyatwa Group of Hospitals, Harare